Globalepolicy.org is a free to access global medical news service for the consumer, professional and researcher.
Our adviser: Drugs Infromation online


             
 

Background: A treatment algorithm and screening examination have been developed to guide patient management and prospectively determine potential for highly active individuals to succeed with nonoperative care after anterior cruciate ligament rupture.

Objective: To prospectively characterize and classify the entire population of highly active individuals over a 10-year period and provide final outcomes for individuals who elected nonoperative care.

Methods: Inclusion criteria included presentation within 7 months of the index injury and an International Knee Documentation Committee level I or II activity level before injury. Concomitant injury, unresolved impairments, and a screening examination were used as criteria to guide management and classify individuals as noncopers (poor potential) or potential copers (good potential) for nonoperative care.

Results: A total of 832 highly active patients with subacute anterior cruciate ligament tears were seen over the 10-year period; 315 had concomitant injuries, 87 had unresolved impairments, and 85 did not participate in the classification algorithm. The remaining 345 patients (216 men, 129 women) participated in the screening examination a mean of 6 weeks after the index injury. There were 199 subjects classified as noncopers and 146 as potential copers. Sixty-three of 88 potential copers successfully returned to preinjury activities without surgery, with 25 of these patients not undergoing anterior cruciate ligament reconstruction at the time of follow-up.

Conclusion: The classification algorithm is an effective tool for prospectively identifying individuals early after anterior cruciate ligament injury who want to pursue nonoperative care or must delay surgical intervention and have good potential to do so.



NAVIGATION


         

 

A saliva test used to diagnose the human immunodeficiency virus (HIV), is comparable in accuracy to the traditional blood test, according to a new study led by the Research Institute of the McGill University Health Centre (RI-MUHC) and McGill University…

 

A cheaper laboratory test that helps guide anti-retroviral drug treatment for people with HIV/AIDS may be just as effective as a more sophisticated test, a group of international researchers has found a discovery that could be particularly important in rural Africa…

 

Testing for HIV when flu-like symptoms develop may offer a cost-effective alternative for early detection of HIV infection in men who have sex with men (MSM), reports a study in the journal AIDS. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health…

 

The odds for effectively detecting HIV in African-American men vary by method, researchers have found. The study, which appears in the Annals of Behavioral Medicine, suggests that HIV-prevention efforts must be multi-faceted, taking into account differences in within this demographic…

 

A cheap, portable blood test kit that requires only a finger prick of blood, and can tell in minutes if you have HIV or syphilis, has proved successful in field tests in Rwanda…

 

A cheap, portable blood test kit that requires only a finger prick of blood, and can tell in minutes if you have HIV or syphilis, has proved successful in field tests in Rwanda…

 

A cheap, portable blood test kit that requires only a finger prick of blood, and can tell in minutes if you have HIV or syphilis, has proved successful in field tests in Rwanda…

 

Promising study results published in the May issue of JAIDS show that a novel medical device has the potential to revolutionize how male circumcision services are offered in countries hardest hit by the HIV epidemic…

 

Promising study results published in the May issue of JAIDS show that a novel medical device has the potential to revolutionize how male circumcision services are offered in countries hardest hit by the HIV epidemic…

 

Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed that InvestorIdeas.com has released an interview with Aethlon CEO Jim Joyce regarding broad spectrum treatment strategies to address HIV, Hepatitis C and other infectious disease conditions…




May 2012
Mon Tue Wed Thu Fri Sat Sun
« Apr    
 123456
78910111213
14151617181920
21222324252627
28293031